<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163719</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-329</org_study_id>
    <nct_id>NCT03163719</nct_id>
  </id_info>
  <brief_title>Impact of Early Lactate Dosage Compared to CK for Diagnosis of a Suspected Seizure</brief_title>
  <official_title>Impact of Early Lactate Dosage Compared to CK for Diagnosis of a Suspected Seizure, on Patient Admitted to an Emergency Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Defining the origin of a seizure remains a difficult diagnosis. The presence of witness is&#xD;
      not systematic, the clinical examination can be little contributory, and the delay&#xD;
      recommended by the FSN is often surpassed for the realization of Creatine kinase (4h). In the&#xD;
      event of a suspected seizure, an initial blood test with Creatine kinase and Lactates is&#xD;
      often done on admission of the patient in other words before the 4hours delay.&#xD;
&#xD;
      It seems interesting to harmonize the practices, to limit the patient wait in the emergencies&#xD;
      for a deferred dosage of CK at 4 hours from the seizure and to identify an early biological&#xD;
      marker.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To evaluate the value of blood CK and Lactate dosage in emergency procedures in the diagnosis&#xD;
      of generalized seizures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to carry out a prospective, observational, monocentric study at the CHU of&#xD;
      Clermont-Ferrand. This is a descriptive analysis of the kinetics of the Creatine kinase and&#xD;
      Lactates rates collected at the admission of a patient consulting for strong suspicion of&#xD;
      convulsive seizure, and at 4 hours from the generalized seizure.&#xD;
&#xD;
      A patient consulting the emergency department for suspected seizure will have an usual blood&#xD;
      test at the admission in this context with notably ionogram, fasting glucose, venous&#xD;
      gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency&#xD;
      department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay.&#xD;
&#xD;
      The Creatine kinase dosage will be collected in the usual way as a &quot;tube bottom&quot;.&#xD;
&#xD;
      As recommended by the French Society of Neurology, a new sample will be collected at 4 hours&#xD;
      of seizure for a dosage of Creatine kinase. The determination of the lactates will be based&#xD;
      on a &quot;tube bottom&quot;.&#xD;
&#xD;
      It is the emergency practitioner who will decide whether or not to include the patient in the&#xD;
      descriptive study, assisted by a standardized survey, enumerating the high probability of&#xD;
      generalized seizure orientation characteristics (patient history, treatments including&#xD;
      antiepileptics, anamnesis, witnesses presence, evocative clinic) The study only recruited&#xD;
      cases of strong suspicion of generalized seizure, beginning less than 4 hours to compare the&#xD;
      kinetics of Creatine kinase and Lactates at admission and 4 hours of the generalized seizure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of lactates measurement and CPK measurement</measure>
    <time_frame>Less than 4 hours</time_frame>
    <description>at admission and four hour after admission for a confirmed convulsive crisis</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Epileptic Seizure</condition>
  <condition>Creatine Kinase</condition>
  <condition>Lactate</condition>
  <condition>Epileptic Generalized Tonic-clonic Seizure</condition>
  <arm_group>
    <arm_group_label>Patients with generalized convulsive seizure</arm_group_label>
    <description>All adult patients (aged at least 18 years old) presenting to the CHU Clermont-Ferrand adult emergencies with a strong suspicion of generalized tonic-clonic seizure beginning less than 4 hours will be included. Each eligible patient will be proposed by a doctor, to participate to the study. The emergency doctor will verify the patient's inclusion and non-inclusion criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CK and Lactate dosages</intervention_name>
    <description>A patient consulting the emergency department for suspected seizure will have an usual blood test at the admission in this context with notably ionogram, fasting glucose, venous gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay. The Creatine kinase dosage will be collected in the usual way as a &quot;tube bottom&quot;. As recommended by the French Society of Neurology, a new sample will be collected at 4 hours of seizure for a dosage of Creatine kinase. The determination of the lactates will be based on a &quot;tube bottom&quot;.</description>
    <arm_group_label>Patients with generalized convulsive seizure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients (aged at least 18 years old) presenting to the CHU Clermont-Ferrand&#xD;
        adult emergencies with a strong suspicion of generalized tonic-clonic seizure beginning&#xD;
        less than 4 hours will be included. Each eligible patient will be proposed by a doctor, to&#xD;
        participate to the study. The emergency doctor will verify the patient's inclusion and&#xD;
        non-inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any generalized convulsive seizure defined by a transient loss of consciousness with&#xD;
             the occurrence of tonic-clonic movements.&#xD;
&#xD;
          -  Beginning less than 4 hours.&#xD;
&#xD;
          -  In a highly evocative context of the crisis by the presence of: witnesses and/or Urine&#xD;
             loss, Tongue bite and/or personal medical history of epilepsy and/or Favorable&#xD;
             context: sleeping debt, drug withdrawal, lights stimulations, video games and/or&#xD;
             Impression of &quot;already lived&quot;, already experienced before the discomfort and/or Break&#xD;
             contact, and/or Unusual posture with hypertonia and/or Amnesia of the episode and/or&#xD;
             Post-episode Confusion&#xD;
&#xD;
          -  Inaugural or recurrent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient Refusal&#xD;
&#xD;
          -  &lt;18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Sepsis, fever&gt; 38 °&#xD;
&#xD;
          -  Shock State&#xD;
&#xD;
          -  Myocardial infarction&#xD;
&#xD;
          -  Unbalanced Diabetes&#xD;
&#xD;
          -  Hepatocellular insufficiency&#xD;
&#xD;
          -  Drug and Toxic Use&#xD;
&#xD;
          -  Taking Metformin&#xD;
&#xD;
          -  Significant muscle injuries&#xD;
&#xD;
          -  Myopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Farès MOUSTAFA</last_name>
    <phone>06 24 36 63 69</phone>
    <email>fmoustafa@chu-clermontferrand.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <contact_backup>
      <last_name>Farès MOUSTAFA</last_name>
      <phone>06 24 36 63 69</phone>
      <email>fmoustafa@chu-clermontferrand.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Arthur RAISON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeannot SCHMIDT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer SAINT-DENIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas DUBLANCHET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>May 22, 2017</last_update_submitted>
  <last_update_submitted_qc>May 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seizure</keyword>
  <keyword>Generalized convulsive seizure</keyword>
  <keyword>Convulsions</keyword>
  <keyword>Creatine Kinase</keyword>
  <keyword>Lactate</keyword>
  <keyword>Lactacidaemia</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Losing consciousness</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Epileptic generalized tonic-clonic seizure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

